hydroxychloroquine

P2, N=7, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting | N=43 --> 7 | Trial primary completion date: Jul 2028 --> May 2026

P4, N=10, Not yet recruiting, University of California, San Francisco | Initiation date: Jan 2026 --> Aug 2026

P2, N=334, Recruiting, Centre Hospitalier Universitaire de Saint Etienne | Not yet recruiting --> Recruiting

In addition, to confirm the pivotal role of AuNPs in ROS generation, AuNPs-treated cells were also cultured in the presence of N-acetylcysteine (NAC; as an antioxidant agent) and hydroxychloroquine (HCQ; as an inhibitor of autophagosome formation). Our finding suggest that AuNPs-induced ROS can promote autophagy and apoptosis via mitochondrial dysfunction and regulation of the ROS/JNK signaling pathway in MCF-7 cancer cells. Thereby highlighting the potential therapeutic value of AuNPs as anticancer agents.

This review provides a systematic analysis of the clinical, biological, and histological characteristics of EF, its associated triggers, and therapeutic strategies based on a comprehensive review of reported cases. We found that poor prognostic factors include diagnostic delay (>6 months), trunk involvement, early-onset disease (<12 years), and morphea-like skin lesions.

P2, N=43, Recruiting, Northwestern University | Trial completion date: Jul 2028 --> Jul 2030 | Trial primary completion date: Jul 2026 --> Jul 2028

The GC203 regimen, combining piggyBac-mbIL-7 autologous TILs with anti-PD-1 antibody, demonstrates favorable safety and promising efficacy in heavily pretreated rOC, which supports its further development in this high-need population.

P2, N=44, Recruiting, Abramson Cancer Center at Penn Medicine | N=66 --> 44

P1, N=20, Active, not recruiting, Fox Chase Cancer Center | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2026 --> Dec 2025

She remained in long-term remission without relapse while receiving prednisolone, tacrolimus, and hydroxychloroquine...Iatrogenic immunodeficiency-associated polymorphic lymphoproliferative disorder resulting in complete remission after tacrolimus withdrawal in a patient with systemic lupus erythematosus has not been previously reported. Clinicians should be aware that iatrogenic immunodeficiency-associated polymorphic lymphoproliferative disorder may occur during tacrolimus use and that discontinuation of the drug may lead to improvement of lymphadenopathy.

P1/2, N=31, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027

P1, N=25, Terminated, University of Utah | Trial completion date: Mar 2029 --> Aug 2025 | Active, not recruiting --> Terminated; Lack of Funding